Tag: FT218

All

FDA Gives Tentative Approval to LUMRYZ, Avadel’s Narcolepsy Drug

The US Food and Drug Administration has granted tentative approval to LUMRYZ, also known as FT218, by Avadel Pharmaceuticals plc.

More Than Half of People with Narcolepsy Report Missing Second Dose of Twice-Nightly Oxybate Therapy
Sodium Oxybate Attributes: Does Once-Nightly Dosing Trump Low Sodium? Avadel Shares Its Findings
Avadel Awaits FDA Decision on Once-Nightly Sodium Oxybate for Narcolepsy; Launch Prep Progressing
REST-ON Trial Data, for Once-Nightly Sodium Oxybate, Published in Peer-Reviewed Journal
Avadel Presents Data from Phase 3 Trial Supporting Clinical Benefit of FT218 in Patients with Narcolepsy
Avadel Presents New Data from Phase 3 Trial of Once-Nightly Sodium Oxybate

All

Once-Nightly Sodium Oxybate Pharmacokinetic Studies Now Available Online

FT218 exhibited a pharmacokinetic profile that supported once-nightly dosing with adequate concentrations maintained throughout the night.

All

Sorry, No Posts Found

Presentation on Investigational Once-Nightly Sodium Oxybate for Narcolepsy Will Take Place at World Sleep 2019 Congress

Sep 23, 2019 | Emerging Compounds, Narcolepsy

Michael Thorpy, MD, director of the Sleep-Wake Disorders Center at the Montefiore Medical Center...

Read More